Danaher Corp /De/ (DHR) Stock Analysis and Metrics

Danaher

NYSE: DHR

$200.18 ▲ +1.13 (+0.57%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap137.16 Bn

P/E37.32

P/S5.54

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)18.48 Bn

Revenue Growth (1y) (Qtr)3.66

Add ratio to table…

About

Danaher Corporation is a global science and technology innovator that designs, manufactures, and markets products and services for the life sciences, diagnostics, and biotechnology sectors. The company enables scientific discovery, healthcare diagnostics, and the development and production of life-saving therapies through its advanced instrumentation, consumables, software, and integrated solutions. Danaher operates with a focus on innovation and operational excellence to support research, clinical decision-making, and biotherapeutic manufacturing worldwide.

Danaher generates revenue primarily through the sale of equipment, consumables, software, and related services across its three core business segments. Its products are used in laboratory research, clinical testing, and biopharmaceutical manufacturing processes. Revenue is derived from both product sales and recurring service contracts, with a strong emphasis on consumables that drive ongoing customer engagement. The company serves a diverse customer base including hospitals, clinical laboratories, research institutions, pharmaceutical and biotechnology companies, and public health organizations globally.

Danaher operates through the following segments: Biotechnology, Life Sciences, and Diagnostics.

• The Biotechnology segment provides equipment, consumables, and services for bioprocessing and discovery applications, supporting the research, development, and manufacturing of biological medicines such as monoclonal antibodies, vaccines, and cell and gene therapies. Its solutions are used by biopharmaceutical companies to advance therapies from early discovery through large-scale production.

• The Life Sciences segment offers instruments, consumables, software, and services used to study biological molecules and cells, including DNA, RNA, proteins, and metabolites. Its products support basic research, drug discovery, and development, with applications in genomics, proteomics, cell analysis, and filtration technologies for industrial and scientific use.

• The Diagnostics segment supplies clinical instruments, consumables, software, and services used in hospitals, physician offices, reference laboratories, and critical care settings to diagnose disease and guide treatment decisions. Its offerings include systems for hematology, immunodiagnostics, molecular testing, and pathology, enabling timely and accurate clinical insights.

Danaher holds a leading position in the life sciences and diagnostics industries, competing with major diversified healthcare and science companies such as Thermo Fisher Scientific, Roche, Siemens Healthineers, and Becton Dickinson. Its competitive advantages stem from a decentralized operating model, continuous investment in innovation through the Danaher Business System, and a strong portfolio of differentiated brands that enable rapid response to market needs and technological change.

The company serves hospitals, clinical and reference laboratories, physician offices, pharmaceutical and biotechnology manufacturers, academic and government research institutions, and public health agencies. Its customers rely on Danaher’s products for diagnostic testing, life science research, and the development and manufacturing of biologics and advanced therapies across the globe.

Investment Thesis

▲ Bull case

Danaher Corporation's strong execution of its Business System is enabling sustained productivity gains and innovation acceleration, creating a durable competitive advantage that the market is underestimating. The company reported adjusted EPS growth of 9.5% year-over-year in Q1 2026 despite a lighter-than-typical respiratory season, demonstrating the resilience of its diversified portfolio and the effectiveness of its operating model in driving cost savings and margin expansion even amid demand softness in specific segments. This ability to grow earnings through operational excellence rather than solely relying on top-line expansion suggests that Danaher can maintain margin improvement trends even if core revenue growth remains modest, providing a floor to profitability that supports multiple expansion. Furthermore, the company's generation of $1.1 billion in free cash flow during Q1 2026, resulting in a 105% conversion ratio to net income, highlights exceptional cash generation capacity that provides significant flexibility for strategic capital deployment, including accretive M&A and shareholder returns, without overleveraging the balance sheet.
The pending acquisition of Masimo represents a strategically compelling opportunity that is not fully reflected in current valuations, as Danaher plans to apply its proven Business System to unlock significant value through both cost and revenue synergies. Management expects the deal to be accretive to adjusted EPS in the first full year post-acquisition and to deliver a high-single-digit return on invested capital by year five, driven by $125 million in cost synergies (including $50 million in gross margin improvements, $50 million in OpEx savings, and $25 million from public company cost elimination) and $50 million in revenue synergies. These synergies are particularly credible given Danaher's successful integration of Radiometer and its deep expertise in acute care diagnostics, where Masimo's mission-critical patient monitoring solutions complement existing offerings and create direct call point opportunities in hospitals. The transaction also strengthens Danaher's position in a growing end market with secular demand drivers, and the company's strong balance sheet and projected $5 billion-plus in annual free cash flow for 2026 provide ample capacity to finance the deal and pursue additional value-creating acquisitions without compromising financial flexibility.
Danaher is positioned to benefit from a multi-year recovery in bioprocessing equipment demand that the market may be underappreciating, as robust consumables growth and improving order trends signal an imminent capacity expansion cycle. Despite flat equipment revenue guidance for 2026, the company reported over 30% year-over-year growth in bioprocessing equipment orders in Q1 2026—the first positive year-over-year comparator in nearly two years—underpinned by strong funnel activity and customer readiness for brownfield debottlenecking and greenfield investments. This trend is supported by sustained monoclonal antibody production growth, a robust pipeline of new biologic drug approvals, and increasing utilization of existing therapies, which together create a growing need for incremental capacity. Danaher's expansive global footprint, deep technical expertise through Cytiva, and leadership in single-use technologies position it to capture significant share of this upcoming investment cycle, with equipment growth likely to accelerate in 2027 and beyond as underinvestment from the past two years reverses, driving both revenue and margin expansion in the bioprocessing segment.
The emerging integration of artificial intelligence across Danaher's portfolio is acting as an underappreciated growth accelerator that will enhance both top-line demand and bottom-line efficiency over the medium to long term. Management highlighted that AI is accelerating the pharma development and commercialization flywheel by improving pipeline yields—currently just above 10%—which in turn drives increased investment in discovery, clinical development, and commercial manufacturing. This creates a self-reinforcing cycle where more successful drug development leads to greater demand for Danaher's Life Sciences tools, bioprocessing solutions, and diagnostics. In the near term, AI is already stimulating demand for automation, analytical instruments, and reagents used in building biologic models, areas where Danaher has strong representation through its expanding AI-enabled offerings. Furthermore, the company is leveraging AI to drive internal productivity gains, with the Danaher Business System and AI becoming synonymous in accelerating cycle times and reducing costs, which will support margin expansion and free cash flow generation independent of external demand trends.
Danaher's international expansion, particularly in high-growth markets like China, is demonstrating resilience and early signs of recovery that are not being fully priced into expectations, especially given the company's diversified exposure across segments. In Q1 2026, core revenue in high-growth markets increased in the low single digits, with mid-single-digit growth in China driven by better-than-expected performance in Biotechnology and Life Sciences, which more than offset the anticipated high-single-digit decline in Diagnostics due to volume-based procurement policies. This performance indicates that Danaher's strategy of leveraging local market dynamics—such as improving biologics monetization through license deals and IPO activity in China—is beginning to bear fruit, and that the worst of the policy-driven headwinds in Diagnostics may be behind us. Additionally, the company noted slightly better-than-expected volume growth in China Satteldiagnostics, an encouraging sign for future demand as the impact of reimbursement changes lapses, suggesting that the diagnostic business in China could stabilize and return to growth sooner than currently anticipated, providing an incremental upside to overall core revenue growth.

Danaher Corporation's strong execution of its Business System is enabling sustained productivity gains and innovation acceleration, creating a durable competitive advantage that the market is underestimating. The company reported adjusted EPS growth of 9.5% year-over-year in Q1 2026 despite a lighter-than-typical respiratory season, demonstrating the resilience of its diversified portfolio and the effectiveness of its operating model in driving cost savings and margin expansion even amid demand softness in specific segments. This ability to grow earnings through operational excellence rather than solely relying on top-line expansion suggests that Danaher can maintain margin improvement trends even if core revenue growth remains modest, providing a floor to profitability that supports multiple expansion. Furthermore, the company's generation of $1.1 billion in free cash flow during Q1 2026, resulting in a 105% conversion ratio to net income, highlights exceptional cash generation capacity that provides significant flexibility for strategic capital deployment, including accretive M&A and shareholder returns, without overleveraging the balance sheet.
The pending acquisition of Masimo represents a strategically compelling opportunity that is not fully reflected in current valuations, as Danaher plans to apply its proven Business System to unlock significant value through both cost and revenue synergies. Management expects the deal to be accretive to adjusted EPS in the first full year post-acquisition and to deliver a high-single-digit return on invested capital by year five, driven by $125 million in cost synergies (including $50 million in gross margin improvements, $50 million in OpEx savings, and $25 million from public company cost elimination) and $50 million in revenue synergies. These synergies are particularly credible given Danaher's successful integration of Radiometer and its deep expertise in acute care diagnostics, where Masimo's mission-critical patient monitoring solutions complement existing offerings and create direct call point opportunities in hospitals. The transaction also strengthens Danaher's position in a growing end market with secular demand drivers, and the company's strong balance sheet and projected $5 billion-plus in annual free cash flow for 2026 provide ample capacity to finance the deal and pursue additional value-creating acquisitions without compromising financial flexibility.
Danaher is positioned to benefit from a multi-year recovery in bioprocessing equipment demand that the market may be underappreciating, as robust consumables growth and improving order trends signal an imminent capacity expansion cycle. Despite flat equipment revenue guidance for 2026, the company reported over 30% year-over-year growth in bioprocessing equipment orders in Q1 2026—the first positive year-over-year comparator in nearly two years—underpinned by strong funnel activity and customer readiness for brownfield debottlenecking and greenfield investments. This trend is supported by sustained monoclonal antibody production growth, a robust pipeline of new biologic drug approvals, and increasing utilization of existing therapies, which together create a growing need for incremental capacity. Danaher's expansive global footprint, deep technical expertise through Cytiva, and leadership in single-use technologies position it to capture significant share of this upcoming investment cycle, with equipment growth likely to accelerate in 2027 and beyond as underinvestment from the past two years reverses, driving both revenue and margin expansion in the bioprocessing segment.
The emerging integration of artificial intelligence across Danaher's portfolio is acting as an underappreciated growth accelerator that will enhance both top-line demand and bottom-line efficiency over the medium to long term. Management highlighted that AI is accelerating the pharma development and commercialization flywheel by improving pipeline yields—currently just above 10%—which in turn drives increased investment in discovery, clinical development, and commercial manufacturing. This creates a self-reinforcing cycle where more successful drug development leads to greater demand for Danaher's Life Sciences tools, bioprocessing solutions, and diagnostics. In the near term, AI is already stimulating demand for automation, analytical instruments, and reagents used in building biologic models, areas where Danaher has strong representation through its expanding AI-enabled offerings. Furthermore, the company is leveraging AI to drive internal productivity gains, with the Danaher Business System and AI becoming synonymous in accelerating cycle times and reducing costs, which will support margin expansion and free cash flow generation independent of external demand trends.
Danaher's international expansion, particularly in high-growth markets like China, is demonstrating resilience and early signs of recovery that are not being fully priced into expectations, especially given the company's diversified exposure across segments. In Q1 2026, core revenue in high-growth markets increased in the low single digits, with mid-single-digit growth in China driven by better-than-expected performance in Biotechnology and Life Sciences, which more than offset the anticipated high-single-digit decline in Diagnostics due to volume-based procurement policies. This performance indicates that Danaher's strategy of leveraging local market dynamics—such as improving biologics monetization through license deals and IPO activity in China—is beginning to bear fruit, and that the worst of the policy-driven headwinds in Diagnostics may be behind us. Additionally, the company noted slightly better-than-expected volume growth in China Satteldiagnostics, an encouraging sign for future demand as the impact of reimbursement changes lapses, suggesting that the diagnostic business in China could stabilize and return to growth sooner than currently anticipated, providing an incremental upside to overall core revenue growth.

▼ Bear case

Danaher Corporation faces significant near-term headwinds in its Diagnostics segment that are being underestimated by management and could persist longer than anticipated, particularly due to structural changes in China's healthcare system that are undermining pricing power and volume trends. Core revenue in Diagnostics declined 4% year-over-year in Q1 2026, driven by continued pressure from volume-based procurement and reimbursement policy changes in China, which management acknowledged as a persistent headwind. While volume growth in China was slightly better than expectations, the ongoing impact of these policies—including centralized bidding and downward price pressure—remains a structural challenge that is unlikely to reverse quickly, especially as local governments prioritize cost containment. Furthermore, the company's reliance on Cepheid's respiratory business, which saw a 25% year-over-year decline due to lighter-than-typical seasonal infection rates, exposes Danaher to volatility in infectious disease trends that are unpredictable and outside its control, making respiratory revenue a less reliable contributor to growth and potentially masking underlying weakness in the broader diagnostics franchise.
The integration of Masimo presents substantial execution risks that could erode the expected synergies and delay the projected return on invested capital, particularly given the complexity of aligning cultures, systems, and go-to-market strategies across two large organizations with overlapping but distinct customer bases. Although Danaher has outlined $125 million in cost synergies and $50 million in revenue synergies by year five, achieving these targets depends on successful integration of sales forces, supply chains, and R&D pipelines—areas where past acquisitions have sometimes fallen short of expectations. Additionally, Masimo's technology and board sales are tied to competitors like Philips and GE Healthcare, which may create channel conflict or customer hesitation as Danaher seeks to expand its influence in acute care settings. The company's assumption that Masimo will be accretive to adjusted EPS in the first full year post-acquisition and deliver a high-single-digit ROIC by year five relies on aggressive execution timelines and conservative amortization assumptions, and any delay in closing or integration could push out these benefits, making the deal less accretive than modeled and potentially weighing on near-term EPS growth.
Danaher's Life Sciences segment is vulnerable to a prolonged downturn in academic and government research funding, which could suppress demand for instrumentation and consumables longer than current guidance assumes, especially as macroeconomic pressures and shifting governmental priorities reduce discretionary spending in basic research. Core revenue in Life Sciences instruments declined low single digits in Q1 2026, primarily due to weakness in North American academic research customers, a trend management acknowledged as expected but potentially more durable than anticipated. While there were early signs of improved funnel activity and recovery in the biotech funding environment, the conversion of funding into actual orders remains uncertain and lumpy, and the company's expectation of positive full-year growth in Life Sciences consumables—despite starting the year slightly negative—depends on a rapid turnaround in academic demand that may not materialize. If funding constraints persist, particularly in the wake of potential budget cuts or reallocations toward applied research, Danaher could face sustained pressure on its Life Sciences franchise, limiting its ability to offset weakness in other segments and constraining overall core revenue growth.
The company's exposure to raw material cost inflation, particularly from petrochemical derivatives linked to volatile oil prices, poses a material risk to gross margins that is not being adequately addressed in current guidance, despite management's claims of vigilance. Although Danaher stated that raw material pressures have not yet been meaningful to its cost position, the company operates in segments—especially Biotechnology and Life Sciences consumables—that are highly sensitive to fluctuations in resin, solvent, and chemical prices, which are directly tied to energy markets. With oil prices subject to geopolitical tensions, including the ongoing conflict in the Middle East, any sustained increase in commodity costs could compress gross margins over time, particularly if the company is unable to fully pass through price increases to customers due to competitive pressures or long-term supply agreements. While Danaher leverages its Business System and contract positions to mitigate volatility, the effectiveness of these tools has limits, and a prolonged period of inflation could force margin contraction or require unplanned cost-cutting initiatives that might undermine growth investments.
Danaher's capital allocation strategy, while strengthened by a strong balance sheet and robust free cash flow, carries the risk of overemphasizing M&A at the expense of organic innovation, potentially leading to integration challenges and diminished returns if acquisitions fail to deliver expected synergies or if core businesses are starved of resources. The company has a sizable M&A funnel and expressed readiness to pursue additional deals beyond Masimo, citing discipline in its three-vector filter, but history shows that even disciplined acquirers can overpay or misjudge cultural and operational fit, especially in fast-evolving technology-driven sectors like life sciences and diagnostics. Furthermore, the pending Masimo deal, valued at approximately $9.9 billion, will significantly increase leverage—projected to reach 2.5 times net debt to EBITDA post-close—requiring substantial free cash flow to deleverage quickly. If integration proves more costly or time-consuming than anticipated, or if unexpected liabilities emerge from the acquisition, Danaher's financial flexibility could be constrained, limiting its ability to invest in organic growth initiatives, return capital to shareholders, or pursue other strategic opportunities, ultimately weighing on long-term value creation.

Danaher Corporation faces significant near-term headwinds in its Diagnostics segment that are being underestimated by management and could persist longer than anticipated, particularly due to structural changes in China's healthcare system that are undermining pricing power and volume trends. Core revenue in Diagnostics declined 4% year-over-year in Q1 2026, driven by continued pressure from volume-based procurement and reimbursement policy changes in China, which management acknowledged as a persistent headwind. While volume growth in China was slightly better than expectations, the ongoing impact of these policies—including centralized bidding and downward price pressure—remains a structural challenge that is unlikely to reverse quickly, especially as local governments prioritize cost containment. Furthermore, the company's reliance on Cepheid's respiratory business, which saw a 25% year-over-year decline due to lighter-than-typical seasonal infection rates, exposes Danaher to volatility in infectious disease trends that are unpredictable and outside its control, making respiratory revenue a less reliable contributor to growth and potentially masking underlying weakness in the broader diagnostics franchise.
The integration of Masimo presents substantial execution risks that could erode the expected synergies and delay the projected return on invested capital, particularly given the complexity of aligning cultures, systems, and go-to-market strategies across two large organizations with overlapping but distinct customer bases. Although Danaher has outlined $125 million in cost synergies and $50 million in revenue synergies by year five, achieving these targets depends on successful integration of sales forces, supply chains, and R&D pipelines—areas where past acquisitions have sometimes fallen short of expectations. Additionally, Masimo's technology and board sales are tied to competitors like Philips and GE Healthcare, which may create channel conflict or customer hesitation as Danaher seeks to expand its influence in acute care settings. The company's assumption that Masimo will be accretive to adjusted EPS in the first full year post-acquisition and deliver a high-single-digit ROIC by year five relies on aggressive execution timelines and conservative amortization assumptions, and any delay in closing or integration could push out these benefits, making the deal less accretive than modeled and potentially weighing on near-term EPS growth.
Danaher's Life Sciences segment is vulnerable to a prolonged downturn in academic and government research funding, which could suppress demand for instrumentation and consumables longer than current guidance assumes, especially as macroeconomic pressures and shifting governmental priorities reduce discretionary spending in basic research. Core revenue in Life Sciences instruments declined low single digits in Q1 2026, primarily due to weakness in North American academic research customers, a trend management acknowledged as expected but potentially more durable than anticipated. While there were early signs of improved funnel activity and recovery in the biotech funding environment, the conversion of funding into actual orders remains uncertain and lumpy, and the company's expectation of positive full-year growth in Life Sciences consumables—despite starting the year slightly negative—depends on a rapid turnaround in academic demand that may not materialize. If funding constraints persist, particularly in the wake of potential budget cuts or reallocations toward applied research, Danaher could face sustained pressure on its Life Sciences franchise, limiting its ability to offset weakness in other segments and constraining overall core revenue growth.
The company's exposure to raw material cost inflation, particularly from petrochemical derivatives linked to volatile oil prices, poses a material risk to gross margins that is not being adequately addressed in current guidance, despite management's claims of vigilance. Although Danaher stated that raw material pressures have not yet been meaningful to its cost position, the company operates in segments—especially Biotechnology and Life Sciences consumables—that are highly sensitive to fluctuations in resin, solvent, and chemical prices, which are directly tied to energy markets. With oil prices subject to geopolitical tensions, including the ongoing conflict in the Middle East, any sustained increase in commodity costs could compress gross margins over time, particularly if the company is unable to fully pass through price increases to customers due to competitive pressures or long-term supply agreements. While Danaher leverages its Business System and contract positions to mitigate volatility, the effectiveness of these tools has limits, and a prolonged period of inflation could force margin contraction or require unplanned cost-cutting initiatives that might undermine growth investments.
Danaher's capital allocation strategy, while strengthened by a strong balance sheet and robust free cash flow, carries the risk of overemphasizing M&A at the expense of organic innovation, potentially leading to integration challenges and diminished returns if acquisitions fail to deliver expected synergies or if core businesses are starved of resources. The company has a sizable M&A funnel and expressed readiness to pursue additional deals beyond Masimo, citing discipline in its three-vector filter, but history shows that even disciplined acquirers can overpay or misjudge cultural and operational fit, especially in fast-evolving technology-driven sectors like life sciences and diagnostics. Furthermore, the pending Masimo deal, valued at approximately $9.9 billion, will significantly increase leverage—projected to reach 2.5 times net debt to EBITDA post-close—requiring substantial free cash flow to deleverage quickly. If integration proves more costly or time-consuming than anticipated, or if unexpected liabilities emerge from the acquisition, Danaher's financial flexibility could be constrained, limiting its ability to invest in organic growth initiatives, return capital to shareholders, or pursue other strategic opportunities, ultimately weighing on long-term value creation.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password